Logo image of ACOG

ALPHA COGNITION INC (ACOG) Stock Fundamental Analysis

NASDAQ:ACOG - Nasdaq - CA02074J5017 - Common Stock - Currency: USD

5.98  +0.46 (+8.33%)

After market: 6.29 +0.31 (+5.18%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ACOG. ACOG was compared to 566 industry peers in the Biotechnology industry. While ACOG has a great health rating, there are worries on its profitability. ACOG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACOG has reported negative net income.
In the past year ACOG has reported a negative cash flow from operations.
ACOG had negative earnings in each of the past 5 years.
In the past 5 years ACOG always reported negative operating cash flow.
ACOG Yearly Net Income VS EBIT VS OCF VS FCFACOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

ACOG has a Return On Assets of -28.85%. This is in the better half of the industry: ACOG outperforms 67.67% of its industry peers.
ACOG has a better Return On Equity (-35.30%) than 73.32% of its industry peers.
Industry RankSector Rank
ROA -28.85%
ROE -35.3%
ROIC N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACOG Yearly ROA, ROE, ROICACOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACOG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACOG Yearly Profit, Operating, Gross MarginsACOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

ACOG has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ACOG has an improved debt to assets ratio.
ACOG Yearly Shares OutstandingACOG Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ACOG Yearly Total Debt VS Total AssetsACOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 4.44 indicates that ACOG is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.44, ACOG is in the better half of the industry, outperforming 79.51% of the companies in the same industry.
There is no outstanding debt for ACOG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.44
ROIC/WACCN/A
WACCN/A
ACOG Yearly LT Debt VS Equity VS FCFACOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 15.00 indicates that ACOG has no problem at all paying its short term obligations.
ACOG has a better Current ratio (15.00) than 90.64% of its industry peers.
A Quick Ratio of 14.81 indicates that ACOG has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 14.81, ACOG belongs to the best of the industry, outperforming 89.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15
Quick Ratio 14.81
ACOG Yearly Current Assets VS Current LiabilitesACOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ACOG have decreased strongly by -40.09% in the last year.
EPS 1Y (TTM)-40.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ACOG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -397.49% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3562.5%
EPS Next 2Y-397.49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACOG Yearly Revenue VS EstimatesACOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 10M 20M 30M
ACOG Yearly EPS VS EstimatesACOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACOG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACOG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACOG Price Earnings VS Forward Price EarningsACOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACOG Per share dataACOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as ACOG's earnings are expected to decrease with -397.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-397.49%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ACOG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA COGNITION INC

NASDAQ:ACOG (5/1/2025, 8:43:59 PM)

After market: 6.29 +0.31 (+5.18%)

5.98

+0.46 (+8.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31 2025-03-31/bmo
Earnings (Next)N/A N/A
Inst Owners39.47%
Inst Owner ChangeN/A
Ins Owners6.55%
Ins Owner Change0.77%
Market Cap95.80M
Analysts82.86
Price Target20.4 (241.14%)
Short Float %0.5%
Short Ratio1.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.43%
Min EPS beat(2)-4.17%
Max EPS beat(2)99.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.31
P/tB 2.33
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-2.99
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS2.59
TBVpS2.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.85%
ROE -35.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15
Quick Ratio 14.81
Altman-Z 4.44
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)12.76%
Cap/Depr(5y)24.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.46%
EPS Next Y-3562.5%
EPS Next 2Y-397.49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year122.94%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.86%
OCF growth 3YN/A
OCF growth 5YN/A